Northern Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.5M | Buy |
974,781
+133,480
| +16% | +$4.96M | ﹤0.01% | 1413 |
|
|
2026
Q1 | $30.6M | Buy |
841,301
+71,478
| +9% | +$3.19M | ﹤0.01% | 1425 |
|
|
2025
Q4 | $35.8M | Sell |
769,823
-40,065
| -5% | -$1.78M | ﹤0.01% | 1317 |
|
|
2025
Q3 | $33.7M | Buy |
809,888
+25,675
| +3% | +$821K | ﹤0.01% | 1364 |
|
|
2025
Q2 | $22.6M | Sell |
784,213
-72,868
| -9% | -$2.25M | ﹤0.01% | 1574 |
|
|
2025
Q1 | $28.7M | Sell |
857,081
-22,733
| -3% | -$849K | ﹤0.01% | 1414 |
|
|
2024
Q4 | $45M | Buy |
879,814
+149,298
| +20% | +$8.35M | 0.01% | 1192 |
|
|
2024
Q3 | $37.3M | Buy |
730,516
+124,479
| +21% | +$6.42M | 0.01% | 1223 |
|
|
2024
Q2 | $27.1M | Buy |
606,037
+4,653
| +0.8% | +$215K | ﹤0.01% | 1365 |
|
|
2024
Q1 | $28.2M | Sell |
601,384
-1,038
| -0.2% | -$40.6K | ﹤0.01% | 1360 |
|
|
2023
Q4 | $21.4M | Buy |
602,422
+5,098
| +0.9% | +$156K | ﹤0.01% | 1567 |
|
|
2023
Q3 | $17.8M | Buy |
597,324
+106,594
| +22% | +$2.2M | ﹤0.01% | 1626 |
|
|
2023
Q2 | $8.84M | Buy |
490,730
+13,442
| +3% | +$268K | ﹤0.01% | 2152 |
|
|
2023
Q1 | $7.67M | Sell |
477,288
-3,512
| -0.7% | -$65K | ﹤0.01% | 2201 |
|
|
2022
Q4 | $8.8M | Buy |
480,800
+2,418
| +0.5% | +$42.6K | ﹤0.01% | 2094 |
|
|
2022
Q3 | $9.39M | Sell |
478,382
-5,899
| -1% | -$120K | ﹤0.01% | 2018 |
|
|
2022
Q2 | $9.03M | Buy |
484,281
+43,757
| +10% | +$873K | ﹤0.01% | 2103 |
|
|
2022
Q1 | $9.67M | Sell |
440,524
-10,004
| -2% | -$202K | ﹤0.01% | 2164 |
|
|
2021
Q4 | $12.8M | Buy |
450,528
+83,529
| +23% | +$2.06M | ﹤0.01% | 2067 |
|
|
2021
Q3 | $7.72M | Buy |
366,999
+885
| +0.2% | +$18.5K | ﹤0.01% | 2463 |
|
|
2021
Q2 | $6.9M | Buy |
366,114
+70,721
| +24% | +$1.24M | ﹤0.01% | 2627 |
|
|
2021
Q1 | $4.51M | Sell |
295,393
-22,143
| -7% | -$343K | ﹤0.01% | 2821 |
|
|
2020
Q4 | $4.48M | Sell |
317,536
-8,145
| -3% | -$113K | ﹤0.01% | 2743 |
|
|
2020
Q3 | $5.1M | Buy |
325,681
+115,751
| +55% | +$1.77M | ﹤0.01% | 2514 |
|
|
2020
Q2 | $3.68M | Buy |
209,930
+47,585
| +29% | +$811K | ﹤0.01% | 2702 |
|
|
2020
Q1 | $2.39M | Buy |
162,345
+13,903
| +9% | +$285K | ﹤0.01% | 2755 |
|
|
2019
Q4 | $3.73M | Buy |
148,442
+12,793
| +9% | +$244K | ﹤0.01% | 2765 |
|
|
2019
Q3 | $2.04M | Buy |
135,649
+27,905
| +26% | +$543K | ﹤0.01% | 3097 |
|
|
2019
Q2 | $2.69M | Buy |
107,744
+3,415
| +3% | +$84.6K | ﹤0.01% | 2897 |
|
|
2019
Q1 | $2.38M | Buy |
104,329
+27,602
| +36% | +$678K | ﹤0.01% | 2967 |
|
|
2018
Q4 | $2.3M | Buy |
76,727
+498
| +0.7% | +$14K | ﹤0.01% | 2969 |
|
|
2018
Q3 | $2.18M | Buy |
+76,229
| New | +$2.26M | ﹤0.01% | 3166 |
|
Other funds holding CRNX
FCM
DCM
JT
Northern Trust's CRNX Position: Q2 2026 in Review
Northern Trust increased its Crinetics Pharmaceuticals (CRNX) stake by 16% in Q2 2026, buying an estimated $4.96M and bringing the position to 974,781 shares worth $36.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1413.
Northern Trust first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $45M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Northern Trust held 974,781 shares of Crinetics Pharmaceuticals worth $36.5M as of Q2 2026.
- Northern Trust bought 133,480 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $4.96M.
- Crinetics Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1413 holding.
- Northern Trust first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Northern Trust's Crinetics Pharmaceuticals position peaked at $45M in Q4 2024.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.